MX2016012880A - Cadena j modificada. - Google Patents

Cadena j modificada.

Info

Publication number
MX2016012880A
MX2016012880A MX2016012880A MX2016012880A MX2016012880A MX 2016012880 A MX2016012880 A MX 2016012880A MX 2016012880 A MX2016012880 A MX 2016012880A MX 2016012880 A MX2016012880 A MX 2016012880A MX 2016012880 A MX2016012880 A MX 2016012880A
Authority
MX
Mexico
Prior art keywords
chain
modified
antibodies
present
binding molecules
Prior art date
Application number
MX2016012880A
Other languages
English (en)
Other versions
MX366588B (es
Inventor
Keyt Bruce
George Presta Leonard
Zhang Fen
BALIGA Ramesh
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of MX2016012880A publication Critical patent/MX2016012880A/es
Publication of MX366588B publication Critical patent/MX366588B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención implica polipéptidos de cadena J recombinantes modificados, moléculas de unión, tal como anticuerpos que los comprenden, y sus usos.
MX2016012880A 2014-04-03 2015-04-02 Cadena j modificada. MX366588B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461974738P 2014-04-03 2014-04-03
PCT/US2015/024149 WO2015153912A1 (en) 2014-04-03 2015-04-02 Modified j-chain

Publications (2)

Publication Number Publication Date
MX2016012880A true MX2016012880A (es) 2017-05-12
MX366588B MX366588B (es) 2019-07-15

Family

ID=52998235

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008359A MX2019008359A (es) 2014-04-03 2015-04-02 Cadena j modificada.
MX2016012880A MX366588B (es) 2014-04-03 2015-04-02 Cadena j modificada.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008359A MX2019008359A (es) 2014-04-03 2015-04-02 Cadena j modificada.

Country Status (21)

Country Link
US (5) US10400038B2 (es)
EP (3) EP4011910A1 (es)
JP (2) JP6744822B2 (es)
KR (3) KR102380402B1 (es)
CN (2) CN106459213B (es)
AU (3) AU2015240595B2 (es)
BR (1) BR112016022841B1 (es)
CA (1) CA2944647C (es)
DK (2) DK3126383T3 (es)
ES (2) ES2887299T3 (es)
HU (2) HUE055693T2 (es)
IL (3) IL278350B (es)
MX (2) MX2019008359A (es)
NZ (1) NZ725568A (es)
PL (2) PL3126383T3 (es)
PT (2) PT3126383T (es)
RU (2) RU2021134101A (es)
SG (2) SG11201608194VA (es)
SI (2) SI3126383T1 (es)
WO (1) WO2015153912A1 (es)
ZA (1) ZA201606906B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6797680B2 (ja) 2013-06-14 2020-12-16 サイオクサス セラピューティクス リミテッド Ｂ型アデノウイルスのための投与計画および製剤
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
WO2019169314A1 (en) * 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020156405A1 (en) * 2019-01-28 2020-08-06 Wuxi Biologics (Shanghai) Co. Ltd. Novel bispecific cd3/cd20 polypeptide complexes
EP4003333A4 (en) * 2019-07-31 2023-11-01 The Wistar Institute for Anatomy and Biology MULTIVALENT DNA ANTIBODIES CONSTRUCTS AND THEIR USE
CN114269785A (zh) * 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
KR20220045030A (ko) * 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
BR112022003282A2 (pt) * 2019-08-23 2022-05-24 Igm Biosciences Inc Glicovariantes de igm
AU2020351205A1 (en) * 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
KR20220070249A (ko) * 2019-09-27 2022-05-30 베이징 스타맵 바이오메드 테크놀로지 리미티드 단일특이적 및 다중특이적 항체
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
CA3245061A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T-CELL RECEIVER MULTIMERS AND THEIR USES

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
EP0642585B1 (en) 1992-05-18 2005-12-28 Genentech, Inc. Activation of oligomerizing receptors by using fused receptor ligands
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US6808709B1 (en) 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
MX9708008A (es) 1995-04-19 1998-03-31 Polymun Scient Immunbio Forsch Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos.
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
EP1015493A1 (en) 1997-01-10 2000-07-05 EPIcyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
WO1999054484A1 (en) 1998-04-20 1999-10-28 The Regents Of The University Of California Modified immunoglobulin molecules and methods for use thereof
SK288176B6 (sk) 1999-01-07 2014-04-02 Zymogenetics, Inc. Farmaceutický prostriedok obsahujúci fúzny proteín, izolovaná molekula polynukleotidu, expresný vektor, kultivovaná bunka, spôsob prípravy polypeptidu a izolovaný polypeptid
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
AU6781700A (en) 1999-08-17 2001-03-13 Health Research Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
US20020168367A1 (en) 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
US7947275B2 (en) 2000-05-10 2011-05-24 Signe Biopharma, Inc. Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth
AU2001277531A1 (en) 2000-07-10 2002-01-21 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
WO2005056601A2 (en) 2003-12-05 2005-06-23 Schreiber John R Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
JP2004514423A (ja) 2000-09-07 2004-05-20 シュライバー，　ジョン　アール． トランスジェニックｘｅｎｏｍｏｕｓｅ（登録商標）から獲得されるｐｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａｌｐｓに対するヒト抗体
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100900176B1 (ko) 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
NZ513418A (en) 2001-08-07 2004-04-30 Univ Massey Vaccine comprising proteins from mycobacterium paratuberculosis
ES2559002T3 (es) 2001-10-23 2016-02-10 Psma Development Company, L.L.C. Anticuerpos contra PSMA
CA2476166C (en) 2002-02-14 2011-11-15 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
ATE477276T1 (de) 2002-03-01 2010-08-15 Immunomedics Inc Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
IL164287A0 (en) 2002-04-12 2005-12-18 Medarex Inc Methods of treatment using ctla-4 antibodies
CA2489467C (en) 2002-06-14 2015-02-24 Immunomedics, Inc. Humanized monoclonal antibody hpam4
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
WO2004013180A2 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
DE602004027483D1 (de) 2003-05-23 2010-07-15 Crucell Holland Bv Herstellung von rekombinanten igm in den per.c6 zellen
TW200510532A (en) 2003-07-15 2005-03-16 Chugai Pharmaceutical Co Ltd IgM production by transformed cell and method of quantifying the same
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
WO2006052641A2 (en) 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
US7251164B2 (en) 2004-11-10 2007-07-31 Innovative Silicon S.A. Circuitry for and method of improving statistical distribution of integrated circuits
WO2006063067A2 (en) 2004-12-09 2006-06-15 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
CA2599734C (en) 2005-03-03 2014-01-28 Immunomedics, Inc. Humanized l243 antibodies
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US20070014720A1 (en) 2005-06-02 2007-01-18 Gadi Gazit-Bornstein Antibodies directed to CD20 and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
RU2008129827A (ru) 2005-12-21 2010-01-27 МЕДИММЬЮН, ЭлЭлСи (US) МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
EP2016173A4 (en) 2006-05-15 2010-06-09 Immunomedics Inc METHOD AND COMPOSITIONS FOR TREATING HUMAN IMMUNODEFECT VIRUS INFECTIONS WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS
EP2021500B1 (en) 2006-05-19 2014-12-31 Children, Youth and Women's Health Service Selective modulation of receptor signalling
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
EP2087111A2 (en) 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
US20100298223A1 (en) 2007-05-02 2010-11-25 Dietmar Rudolf Fries Fibrinogen for treatment of bleeding in trauma and platelet disorders
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
EP2195342A1 (en) 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2219458B1 (en) 2007-11-08 2015-07-15 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
CN102149727A (zh) 2008-07-11 2011-08-10 航道生物技术有限责任公司 包含抗体替代卡帕轻链序列的构建体和文库
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
EP2509997B1 (en) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
US9085623B2 (en) 2010-02-11 2015-07-21 Alexion Pharmaceuticals, Inc. Therapeutic methods using anti-CD200 antibodies
WO2012054077A2 (en) 2010-10-19 2012-04-26 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
MX2014004980A (es) 2011-10-24 2014-09-11 Abbvie Inc Inmunoaglutinantes biespecificos dirigidos contra tnf e il-17.
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
CA2863714C (en) 2012-02-08 2022-07-05 Igm Biosciences, Inc. Cdim binding proteins and uses thereof
AU2013244916B2 (en) 2012-04-05 2017-08-03 Gottfried Himmler Secretory immunoglobulin complex
ES2655077T3 (es) * 2012-04-17 2018-02-16 Mayo Foundation For Medical Education And Research Anticuerpos humanos y secuencias de unión específicos del mismo para uso en accidente cerebrovascular e isquemia y condiciones isquémicas
US20150175678A1 (en) 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
CN103570821A (zh) * 2012-07-27 2014-02-12 北京智飞绿竹生物制药有限公司 粘蛋白-1抗原性多肽及其作为肿瘤疫苗的用途
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014124457A1 (en) 2013-02-11 2014-08-14 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CA2922830A1 (en) 2013-09-05 2015-04-16 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
NZ720353A (en) 2013-12-30 2019-12-20 Epimab Biotherapeutics Inc Fabs-in-tandem immunoglobulin and uses thereof
CA2936877C (en) 2014-01-16 2023-03-28 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
AU2015213593B2 (en) 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
KR102380402B1 (ko) 2014-04-03 2022-03-31 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
EP3750918A1 (en) 2015-01-20 2020-12-16 IGM Biosciences, Inc. Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
CN115093479A (zh) 2015-03-04 2022-09-23 Igm生物科学股份有限公司 Cd20结合分子及其用途
JP6882184B2 (ja) 2015-03-25 2021-06-02 アイジーエム バイオサイエンシズ インコーポレイテッド 多価ｂ型肝炎ウイルス抗原結合分子およびその使用
WO2016168758A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
DK3355913T3 (da) 2015-09-30 2024-12-02 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
PL3455257T3 (pl) 2016-05-09 2022-01-17 Igm Biosciences Inc. Przeciwciała anty-pd-l1
US20190330360A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
EP3496536A4 (en) 2016-07-20 2020-02-12 IGM Biosciences, Inc. MULTIMERE CD40-BINDING MOLECULES AND USES THEREOF
US20190330374A1 (en) 2016-07-20 2019-10-31 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
US20190338040A1 (en) 2016-07-20 2019-11-07 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
US20200392239A1 (en) 2018-02-26 2020-12-17 Igm Biosciences, Inc. Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
WO2019169314A1 (en) 2018-03-01 2019-09-06 Igm Biosciences, Inc. IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
KR20210083260A (ko) 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 다가 IgM- 및 IgA-Fc 기반 결합 분자
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
CN114269785A (zh) 2019-08-15 2022-04-01 Igm生物科学股份有限公司 免疫刺激性多聚体结合分子
KR20220045030A (ko) 2019-08-17 2022-04-12 아이쥐엠 바이오사이언스 인코포레이티드 다량체성 이중특이적 항-cd123 결합 분자 및 이의 용도
BR112022003282A2 (pt) 2019-08-23 2022-05-24 Igm Biosciences Inc Glicovariantes de igm
AU2020351205A1 (en) 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
BR112022013071A2 (pt) 2020-01-06 2022-09-20 Igm Biosciences Inc Moléculas de ligação multiméricas altamente sialiladas
US20230212293A1 (en) 2020-04-22 2023-07-06 Igm Biosciences, Inc. Pd-1 agonist multimeric binding molecules
MX2022014259A (es) 2020-05-12 2022-12-07 Igm Biosciences Inc Uso de una molecula de union anti-dr5 multimerica en combinacion con una terapia contra el cancer para tratar el cancer.
CA3187008A1 (en) 2020-07-27 2022-02-03 Paul R. Hinton Multimeric coronavirus binding molecules and uses thereof
US20240002526A1 (en) 2020-11-17 2024-01-04 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
WO2022177870A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
MX2023009615A (es) 2021-02-17 2023-08-24 Igm Biosciences Inc Moleculas de union anti-cd123 y usos de estas.

Also Published As

Publication number Publication date
BR112016022841A2 (pt) 2017-10-17
EP3560954B1 (en) 2021-08-04
US20170283510A1 (en) 2017-10-05
US10400038B2 (en) 2019-09-03
DK3126383T3 (en) 2019-04-01
SG10201909716RA (en) 2019-11-28
BR112016022841B1 (pt) 2023-09-26
KR102380402B1 (ko) 2022-03-31
KR20220044377A (ko) 2022-04-07
JP7062025B2 (ja) 2022-05-02
HUE055693T2 (hu) 2021-12-28
MX2019008359A (es) 2019-09-16
SI3126383T1 (sl) 2019-05-31
PL3560954T3 (pl) 2021-12-13
AU2020201347A1 (en) 2020-03-12
AU2015240595A1 (en) 2016-11-03
CN112759650A (zh) 2021-05-07
US20190002566A1 (en) 2019-01-03
KR20230155600A (ko) 2023-11-10
CN106459213A (zh) 2017-02-22
EP4011910A1 (en) 2022-06-15
US20200190190A1 (en) 2020-06-18
AU2015240595B2 (en) 2020-02-27
EP3126383B8 (en) 2019-02-27
IL248151A0 (en) 2016-11-30
DK3560954T3 (da) 2021-09-06
EP3560954A1 (en) 2019-10-30
RU2021134101A (ru) 2022-03-22
CA2944647C (en) 2025-07-08
SG11201608194VA (en) 2016-10-28
EP3126383A1 (en) 2017-02-08
PL3126383T3 (pl) 2019-08-30
US11555075B2 (en) 2023-01-17
KR20160142345A (ko) 2016-12-12
CN112759650B (zh) 2024-10-01
AU2022201585A1 (en) 2022-03-31
AU2020201347B2 (en) 2022-03-10
JP2020114828A (ja) 2020-07-30
BR112016022841A8 (pt) 2018-06-12
CN106459213B (zh) 2020-12-01
US20230279111A1 (en) 2023-09-07
CA2944647A1 (en) 2015-10-08
RU2016141579A3 (es) 2018-12-26
HUE042829T2 (hu) 2019-07-29
JP6744822B2 (ja) 2020-08-19
NZ725568A (en) 2022-10-28
MX366588B (es) 2019-07-15
PT3126383T (pt) 2019-03-22
RU2761118C2 (ru) 2021-12-06
US20170183409A1 (en) 2017-06-29
EP3126383B1 (en) 2018-12-19
RU2016141579A (ru) 2018-05-10
SI3560954T1 (sl) 2021-11-30
ZA201606906B (en) 2021-07-28
WO2015153912A1 (en) 2015-10-08
ES2887299T3 (es) 2021-12-22
US10975147B2 (en) 2021-04-13
ES2717704T3 (es) 2019-06-24
PT3560954T (pt) 2021-09-07
JP2017512815A (ja) 2017-05-25
IL292311A (en) 2022-06-01
US9951134B2 (en) 2018-04-24
IL278350B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
MX2016012880A (es) Cadena j modificada.
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CY1124004T1 (el) Υποδορια σκευασματα αντισωματων αντι-cd38 και οι χρησεις τους
CL2018000431A1 (es) Anticuerpos anti-bcma, moléculas de unión de antígeno específicas que vinculan bcma y cd3, y sus usos relacionados.
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
ECSP18000844A (es) Anticuerpos de unión a tau
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
CL2016001871A1 (es) Anticuerpos humanos para pd-1
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CL2015002742A1 (es) Moléculas de unión para bcma y cd3.
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
DK3328891T3 (da) Antistofkonstruktioner til flt3 og cd3
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
CR20150049A (es) Anticuerpos e inmunoconjugados anti-cd79b
ECSP17023281A (es) Inhibidores de mk2 y sus usos
ECSP18000887A (es) Anticuerpos de unión a tau
DK3107938T3 (da) Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
MX378112B (es) Anticuerpos que potencian el factor h y sus usos.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: IGM BIOSCIENCES INC.

GB Transfer or rights

Owner name: IGM BIOSCIENCES INC.

FG Grant or registration